MSDC-0160 (Mitoglitazone; CAY-10415)

Description: MSDC-0160 (also called CAY10415), a thiazolidinedione analog, is the prototypical mTOT(mitochondrial target of thiazolidinediones)-modulating insulin sensitizer being investigated to treat diabetes and Alzheimer's disease. It is an insulin sensitizer without the peroxisome proliferator–activated receptor-gamma (PPAR-gamma)-dependent side effects. Co-incubation of islets with MSDC-0160 and IGF-1 reduces the resistance of insulin-signaling pathway and preserves insulin content. MSDC-0160 at 50uM alone also prevents the loss of insulin content significantly. Besides that, treatment of MSDC-0160 increases the phosphorylation of AMPK and reduces mTOR phosphorylation. Moreover, MSDC-0160 is also found to display pro-survival effects in human islets via reducing the level of cleaved caspase-3 and increasing the expression of apoptosis-related genes such as bcl2.

References: PLoS One. 2013 May 1; 8(5):e62012; Gene Regul Syst Bio. 2007 Sep 17; 1:73-82.